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Abstract-Thrombin is the central enzyme of haemostasis. Information on the production and 
inhibition of thrombin in plasma is important for evaluating the state of the coagulation system. 
Measurement of thrombin generation in plasma using small oligopeptide chromogenic substrates 
gives rise to a signal that not only reflects the enzymatic activity of free thrombin, but also 
contains a contribution of the complex of thrombin with one of its inhibitors, a,-macroglobulin. 
This paper describes a mathematical procedure to extract from the measured curves the signal 
due to free thrombin only. The time integral of this free thrombin curve, which we call the 
thrombin potential, is a parameter which condenses much of the information present in such a 
curve. Thrombin production from prothrombin can be calculated from the concentration of free 
thrombin, when the rate constants governing the decay of thrombin are known. It is described 
how this calculation can be performed, accounting for the consumption of some of the inhibitors 
of thrombin during coagulation. Measurement of the time integral of the thrombin concentration 
promises clinical applicability of thrombin generation tests. It is based on the continuous 
registration of conversion of chromogenic substrate by thrombin during coagulation in plasma. It 
is shown how the curves obtained by this test can be analysed by a procedure which is analogous 
to the analysis of curves measured by subsampling from clotting plasma. 
Blood coagulation Thrombin Plasma Kinetics Inhibition Production 
INTRODUCTION 
Thrombin plays a central role in the coagulation system. Its adequate production at the 
site of a vascular lesion is pivotal in arresting bleeding. The importance of thrombin 
generation is easily understood from the serious problems that arise in haemophiliacs in 
which the mechanism of thrombin generation is defective. Even more important is 
thrombosis, which is the major cause of death in our society (coronary infarction, 
stroke). Thrombosis can be prevented by inhibition of thrombin generation in one way 
or another [ 11. 
Initial traces of thrombin are formed by activation of its precursor zymogen prothrom- 
bin, upon the exposure to blood or plasma of tissue factor from damaged tissue. These 
thrombin traces trigger the activation of much larger amounts of prothrombin by 
feedback activation of blood platelets [2] and the cofactors V and VIII [3-51. The 
generation of thrombin is influenced by every type of antithrombotic therapy, as well as 
by most coagulation disorders [l]. Measurement of the time course of thrombin 
concentrations in clotting plasma, giving rise to a thrombin generation curve, therefore 
yields important information about the functioning of the coagulation system [6]. As a 
useful parameter, summarizing much of the information of a thrombin generation curve, 
we coined the thrombin potential [7], which is defined as the time integral of the free 
thrombin concentration. In addition, information on the mechanism whereby the 
thrombin concentration is affected can be gained by deriving the rate of production of 
thrombin from thrombin generation curves [8]. 
t Present address: Department of Molecular Medicine, Mount Sinai School of Medicine, 1 Gustave Levy 
Place, Box 1269, New York, NY 10029, U.S.A. 
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Fig. 1. Reaction scheme of thrombin production and inactivation. 
Thrombin generation curves are measured using chromogenic oligopeptide substrates. 
This assay method is based on the ability of thrombin to cleave off the para-nitroaniline 
(pNA) group of the substrate, altering its light absorption spectrum [9]. The concentra- 
tion of thrombin determines the rate of change of optical density at 405 nm. Using this 
method, thrombin concentrations are determined in subsamples drawn from clotting 
plasma at timed intervals (usually 30 set) [8]. 
Unfortunately, chromogenic substrates are not completely specific for thrombin. In 
particular, the physiologically inactive complex of thrombin with one of its inhibitors, 
a,-macroglobulin (az-M), converts small chromogenic substrates almost as well as free 
thrombin does. This is because a,-macroglobulin does not bind the active centre of 
thrombin, but still impedes the binding and conversion of large, physiologically import- 
ant (protein) substrates [lo-121. Therefore, the conversion of chromogenic substrate is 
due to both free thrombin and the az-macroglobulin-thrombin complex. Full interpre- 
tation of the raw experimental data necessitates the translation of the measured rates of 
chromogenic substrate conversion (amidolytic activity) into a time curve of the free 
thrombin concentration, by subtracting the part of the signal due to 
a,-macroglobulin-thrombin. This also enables calculation of the thrombin potential. 
The time course of free thrombin is the result of transient thrombin production from 
prothrombin on the one hand, and inactivation of thrombin by inhibitors present in 
plasma on the other (Fig. 1). In order to calculate the time course of thrombin formation 
from prothrombin, information is therefore needed on thrombin breakdown in plasma. 
Thrombin is inactivated by several plasma proteins. The main pathway consists of 
complex formation with antithrombin III (ATIII), but several other inhibitors, such as 
a,-antitrypsin and a,-macroglobulin, are active as well [8, 131. The concentration of 
antithrombin III is not much higher than the prothrombin concentration. Thus, a 
considerable amount of antithrombin III is consumed during blood clotting in a plasma 
sample [14-161. The inactivation rate of thrombin is proportional to the product of the 
thrombin and AT111 concentrations and therefore declines with increasing AT111 
consumption [ 161. 
Measuring thrombin generation in subsamples from clotting plasma is not a routine 
undertaking, as it takes an experienced technician more than an hour of work. We 
recently described a technique to measure the integral of the thrombin concentration 
continuously in a cuvette [17]. Since no subsampling is required, the technique has the 
potential of being automated and used routinely in a hospital laboratory. It is based on 
the presence of a chromogenic substrate in clotting plasma. Thrombin, while it is being 
produced and inactivated in the plasma, converts the chromogenic substrate. The rate of 
conversion of chromogenic substrate at any moment indicates the amount of enzymatic 
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activity, so that the optical density vs time curve represents the time integral of the 
thrombin and a,M-thrombin concentration. Since the concentration of chromogenic 
substrate used is below its K,, consumption of the substrate results in a lower reaction 
rate. This, however, can be corrected for mathematically, since the exact concentration 
of chromogenic substrate can be inferred from the value of the optical density at any 
time. To analyse the integral thrombin vs time curve, it can be converted in a normal 
thrombin generation curve by calculating its first derivative. The thrombin potential, 
however, can be calculated directly from the measured curve. 
Thus, analysis of measured thrombin generation curves consists of the following steps. 
(1) Correction of the observed amidolytic activities for the a,M-thrombin activities, 
which results in a time activity curve of free thrombin. 
(2) Calculation of the thrombin potential as the area under the latter curve. 
(3) Calculation of the rate of thrombin production from the above time activity curve 
using independent estimates of the thrombin inactivation rate. 
Additionally, integral thrombin generation curves can be corrected for substrate con- 
sumption, and stripped from the activity due to the a,M-thrombin complex. 
METHODS 
Thrombin generation measured by chromogenic assay of subsamples from clotting 
plasma 
This method is described in full detail in ref. [8]. Briefly, to 240~1 of plasma was added 
60~1 of a buffer (buffer A, 50 mM Tris-HCl, 100 mM NaCl, 0.5 mg/ml bovine albumin, 
pH 7.35), containing any substance under investigation. Clotting was initiated by 
addition of 60~1 of a solution containing 100 mM CaClz and human brain thromboplastin 
in a suitable dilution. At timed intervals, 10~1 subsamples were diluted into a cuvette 
with 490~1 of a buffer (buffer B, 50 mM Tris-HCl, 175 mM NaCl, 20 mM EDTA, 
0.5 mg/ml bovine albumin, pH 7.90), containing 2OOpM of the chromogenic substrate 
S2238 (Kabi, Sweden). Amidolysis of the chromogenic substrate in the cuvette was 
allowed to proceed for approximately 2 min. This reaction was then halted by the 
addition of 300~1 of 1 M citric acid. The precise moments of subsampling and stopping 
were recorded on a personal computer by means of push-button equipped pipettes. 
Optical densities were measured at 405 nm and converted into amidolytic activities 
(mOD/min) by dividing by the reaction times. Thus, the result of such a thrombin 
generation experiment is a series of amidolytic activities with corresponding time points. 
Figure 2 shows a typical curve of amidolytic activity obtained in pooled normal plasma. 
The steady end level of this curve is caused by the activity of the a,M-thrombin complex. 
Experimental determination of the decay constants of thrombin 
The overall decay constant k,,, of thrombin in plasma can be determined experimen- 
tally [16] by addition of thrombin to plasma and measuring the time course of its 
disappearance. This was done essentially in the same way as described above for 
measurement of thrombin generation. The amidolytic activities E(t) as obtained in the 
experiment can be fitted to the following exponential: 
E(t) = E( 03) + (E(0) - E( 00)) e-kta” (1) 
where E(0) is the initial amidolytic activity, and E( m ) is the steady end level of 
amidolytic activity due to the azM-thrombin complex. The steady end level E(m) can 
reliably be determined by measuring several late points of the curve, and thus needs not 
be fitted. 
Thrombin generation measured by recording the time integral of thrombin in plasma 
This method for measuring thrombin generation pseudo-continuously is described in 
detail in ref. [ 171. In brief, 400~1 of reptilase defibrinated plasma, 100~1 of buffer A 
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Fig. 2. Time course of the amidolytic activity. The time course was measured in a subsampled 
thrombin generation experiment carried out as described in normal pooled plasma. Coagulation 
was triggered at time zero with human brain thromboplastin diluted 240-fold and Ca2+ 
(16.7 mM). 
containing any substance under investigation, and 60~1 of the chromogenic substrate 
SQ68 (methylmalonyl-methylalanyl-arginyl-pNA, from Serbio, France) were added to a 
cuvette at 37°C. The chromogenic substrate SQ 68 was used in these experiments instead 
of S2238, because of its more suitable kinetic properties, as discussed further below. 
Clotting was triggered by addition of 40,ul of tissue factor in 0.25 M CaCI,. The time 
course of optical density at 405 nm was then recorded at a rate of two optical density 
readings per sec. The chromogenic substrate in the cuvette was continuously converted 
by the thrombin being produced and broken down. The resulting optical density vs time 
curve is the time integral of a thrombin generation curve. The final slope of this curve is 
the result of the amidolytic activity of the a,M-thrombin complex. Figure 3 shows an 
example of a typical time course of optical density in pooled normal plasma 
150 
75 
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Fig. 3. Continuous measurement of the time integral of the thrombin concentration. The time 
course of the optical density (in mOD) was measured in an integral thrombin generation 
experiment carried out as described, in normal pooled plasma. Coagulation was triggered at time 
zero with human brain thromboplastin diluted 240-fold and Ca*+ (16.7mM). The SQ 68 
concentration was SOOpM. 
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Calculation of the free thrombin concentration from thrombin generation curves 
The experimentally determined amidolytic activity E at time t is the result of both the 
thrombin concentration T and the concentration of the az-macroglobulin-thrombin 
complex MT. Since the K, values of thrombin and the alM-thrombin complex for 
conversion of S2238 are very much lower than the actual concentration of S2238, the 
reaction velocity is linear with the thrombin and a,M-thrombin concentrations: 
so that 
E(t) = k,,, - T(t) + katz - MT(t), (2) 
E(t)lk,,,, =A(t) = T(t) +f’MT(t), (3) 
with A(t) as the amidolytic activity converted to nM of thrombin activity, k,,,, and kcar2 
being the catalytic constants for conversion of S2238 of thrombin and a,M-thrombin, 
respectively, the f being the reaction rate of substrate conversion by a2M-thrombin 
relative to the reaction rate of an equal concentration of thrombin, i.e. f = k,,tzlk,t,. The 
value of f has been determined at 0.556, whereas the value for k,,, in our system is 
186 see-’ [8]. 
Thrombin breakdown by a,M is an apparent first-order process [8], so that the rate at 
which the complex of thrombin and a,M forms is linearly dependent on the thrombin 
concentration: 
dMT 
,,=k,.T(t)=k,[A(t)+W-(t)]. 
Experimentally, an array of values A(ti) is measured. Assuming the value of the 
first-order decay constant for a,M (kJ is known, numerical integration of equation (4) 
yields the values for MT(ti). When the time between two subsequent samples is not too 
long (less than about 45 set for a usual thrombin generation curve), numerical integ- 
ration using Eulers method gives adequate precision. The array of thrombin concentra- 
tions is then calculated by: 
T(ti)=A(ti)-f.MT(ti). (5) 
Figure 4 shows a measured time curve of amidolytic activity and the thrombin vs time 
curve derived from it. 
150 
5 10 15 
time (min) 
Fig. 4. A thrombin generation curve and the calculated time course of the free thrombin 
concentration. 0: The experimentally determined amidolytic activity; 0: free thrombin as 
calculated from the amidolytic activity and the atM-dependent decay constant (k,). 
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The value of k2 can be obtained experimentally as reported [8]. Alternatively, it can be 
obtained from the amidolytic activity vs time curve, since the complex of a,M and 
thrombin has residual amidolytic activity. First, time courses of the free thrombin 
concentration are calculated from the amidolytic activity values as described above, 
using a range of values K for f* k2. Using equation (4) it is derived that these calculated 
thrombin concentrations T, are related to the real (but unknown) thrombin concentra- 
tions Tin the following manner: 
T,,(t) = T(t) + (f*k2 - 1~) 
I 
’ e-“(‘-‘)T(t) dr. (6) 
0 
If it is assumed that prothrombin conversion has stopped at a time point t,, then: 
T(t) = T(t,) . e-(ki+kz)(‘-b), tat,_ (7) 
If it is further assumed that k, + k,* kZ, then the terms with e-(kl+k2)(r-~) can be 
neglected, and T, can be approximated by: 
T,(t)=(f.k,- Ic)C+e-“(‘-‘o), (8) 
where 
e-K(‘o-S)T(s) d.s + k +F _ K. 
12 
Thus, T,(t)le- ‘(‘--l0) remains a constant value for a given 1c after time point to, a 
property that we used to test the validity of the assumptions. When K is equal to f- k,, the 
value of Tw(t)le-Y(‘-~) is zero. T,(t)le- +--IO) is then plotted as a function of K, and k2 is 
calculated from the intersection of this function with the horizontal axis. This intersec- 
tion can be determined using the bisection method. 
Calculation of the rate of prothrombin conversion from time curves of the free 
thrombin concentration 
The rate of change (V) of the thrombin concentration (T) in plasma is the difference 
of the rate of thrombin production (=prothrombinase activity, P) and the rate of 
thrombin breakdown (D): 
V(t) = dT/dt = P(t) - D(t). (10) 
V(t) can be obtained from the series of thrombin concentrations T(t) which are 
calculated from the measured course of the amidolytic activity E(t). D(t) is determined 
from the independently measured thrombin decay constants and the thrombin concen- 
tration T(t). The rate of prothrombin conversion P(t) is then calculated by adding D(t) 
and V(f) for each time point. 
Thrombin decay. Thrombin in plasma is inhibited by a number of serine protease 
inhibitor proteins (I), giving rise to an essentially irreversible complex IT: 
T+I:IT, 
where k’ is the second-order rate constant of thrombin inhibition by the inhibitor. 
The rate of formation of IT is then given by the second-order rate equation: 
dIT dl 
-=-,,=k’.Z(r).T(t). 
dt (11) 
Serine protease inhibitors relevant to thrombin breakdown in plasma are antithrom- 
bin III (ATIII), aTmacroglobulin (cQM), heparin cofactor II (HCII), and a number of 
serpins with a relatively unimportant contribution to the anti-thrombin activity (R). The 
concentration of the most important physiological thrombin inhibitor AT111 is not much 
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higher than the prothrombin concentration, so that during the course of coagulation the 
concentration of AT111 decreases considerably [14-161. The rate of thrombin breakdown 
due to AT111 decreases to the same extent, since it is linearly proportional to the AT111 
concentration. In the presence of dermatan sulphate, HCII becomes an effective 
inhibitor, and in this situation consumption of the inhibitor plays an even bigger role, 
since the plasma concentration of HCII is about two-thirds of the plasma concentration 
of prothrombin. In the absence of dermatan sulphate, no inhibitory action of HCII can 
be detected. The plasma concentration of a,M is relatively high (3.5pM) and does not 
decrease significantly during coagulation, nor does the concentration of the group of 
inhibitors of secondary importance. Therefore, it is reasonable to assume first-order 
kinetics for the inactivation of thrombin by these inhibitors. The rate of inactivation of 
thrombin is then given by: 
D(t)=(k;.ATZZZ(r)+k;-HCZZ(t)+k,+k,).T(t), (12) 
where k2 = k;.a,M and k3 = k;* R, k: represent the second-order rate constants for the 
various inhibitors. The time courses of the AT111 and HCII concentrations are calculated 
from: 
dA TZZZ(t) 
dt 
= - k;*ATZZZ(t).T(t) (1% 
dHCZZ(t) 
dt 
= - k;*HCZZ(t). T(t). Wb) 
The overall first-order decay constant of thrombin in plasma containing the initial 
concentrations of AT111 and HCII is determined as described in the Methods section. 
This overall constant can be attributed to the various inhibitors as follows. The a,M 
dependent decay constant k2 can be inferred directly from a thrombin generation curve, 
as described above. It can also be determined experimentally as reported [8]. The value 
of k3 has been found to be fairly invariable between individuals at 0.17 min-’ [16]. Since 
usually the HCII-dependent decay does not play a role, the value of kl is then calculated 
as k,,, - k2 - k3. The second-order constant k; for the ATIII-thrombin reaction in the 
absence of any potentiating substance, such as heparin or a heparin derivative, has been 
determined at 1.508 min-’ -,uM-’ [ 161. This value can then be used to calculate the initial 
AT111 concentration from the first-order constant k, as follows: 
ATZZZ(0) = k,lk;. (14) 
Using the decay constants and the initial AT111 concentration thus obtained, equations 
(12) and (13) can be integrated numerically to calculate the time course of the thrombin 
decay rate D(t) and the concentrations of the thrombin inhibitor complexes. Again, 
Eulers method is of sufficient accuracy if the time intervals are not too long (<45 set). 
Figure 5 shows D(t), V(t) and P(t) for a typical thrombin generation experiment. Figure 
6 shows the time course of the thrombin-inhibitor complexes in the same experiment. 
Heparin. Heparin increases the inhibitory capacity of AT111 for thrombin. It acts as a 
catalyst, since it associates reversibly with AT111 and it is liberated upon formation of the 
irreversible ATIII-thrombin complex [ 181. The complex of AT111 and heparin is a much 
more effective inhibitor for thrombin than AT111 alone, because the overall association 
rate of thrombin with the ATIII-heparin complex is three orders of magnitude higher 
[191. 
Heparin binds to AT111 with a K,, of about 180 nM [19], and is normally present in 
concentrations much lower than the concentration of ATIII, itself present at about 
1.5pM. Thus, all heparin would be expected to bind to ATIII. However, in plasma the 
situation is complicated by the competition of AT111 and other plasma proteins for 
heparin. One example of a heparin binding protein is histidin rich glycoprotein (HRGP), 
which has a plasma concentration of -5pM and binds heparin with high affinity 
(&=7nM). 
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Fig. 5. Velocities of decay and formation of thrombin. The velocity of thrombin decay (0) was 
determined from the thrombin generation curve of Fig. 2 and the independently measured 
thrombin decay constants. Together with the first derivative of the thrombin concentration in 
time (0), this determines the velocity of prothrombin conversion, also known as the prothrombi- 
nase activity (0). 
The concentration of the ATIJI-heparin complex (AH) in the presence of heparin 
(H), ATIII, with dissociation constant K,,, and one other heparin binding protein (B) 
with a dissociation constant K,,,, is given by: 
Il.ATIII 
AH=H 
L. ATIII+ K,,, 
with 
K 
A=_?_-_ 
B + KDb’ 
(154 
Wb) 
In the case of K,,BL.ATIII, as is true for HRGP (K,,,- 160nM, 1.ATIII-2 nM), 
equation (15) reduces to: 
AH=; H.ATIII, 
Da 
(16) 
800 
400 
0 
0 5 10 15 
time (min) 
Fig. 6. Thrombin inhibitor complexes. The time course of the concentrations of various throm- 
bin inhibitor complexes as calculated from the thrombin generation curve of Fig. 2 and the 
measured thrombin decay constants. 0: Thrombin-AT III; 0~ thrombin-a2M; 0: the complex 
of thrombin with other minor thrombin inhibitors. 
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which shows that the concentration of the ATIII-heparin complex is indeed linearly 
proportional to the AT111 concentration in the presence of heparin under the above 
conditions. The presence of several species of heparin binding proteins does not affect 
this property. Equation (16) is the basis for the definition of the specific antithrombin 
activity of a heparin. This is defined as the increase of k, caused by 1 ug of heparin per ml 
plasma normalized to an AT111 level of 1 uM [ 161. The rate of inhibition of thrombin due 
to ATIII-heparin (DAH) can now be described by: 
D&f) =kAH.AH(t).T(t) =k,,; Zf~ATZZZ(t)~T(t) 
Da 
= 4’. hep .H.ATZZZ(f). T(t). (17) 
Assuming that AH4 ATIII, the total rate of inhibition is now given by 
D(f)=](k;+k;,, .H)-ATZZZ(f)+k;-Z-ZCZZ(t)+k,+k,].T(r) 
= [k;,hep .A TZZZ(t) + k;.HCZZ(t) + k2 + k3] - T(t). (18) 
The new second-order rate constant k;, hep, describing thrombin inactivation by 
ATIII-heparin and by AT111 alone, can then be calculated from the first-order rate 
constant k, as follows: 
k;.hpe = (k,,, - k2 - k3)lA Z-111(0). (19) 
The decay of thrombin brought about by heparin cofactor II is normally of no 
importance. If, however, dermatan sulphate or a related substance is present in plasma, 
it has to be considered [20]. In such a case, the initial concentration of HCII has to be 
determined in plasma devoid of ATIII. 
Calculation of the time integral of the free thrombin concentration from integral 
thrombin generation curves 
This assay is based on the continuous conversion of chromogenic substrate by 
thrombin being produced and inactivated in plasma. However, also the a,M-thrombin 
complex has the ability to cleave the chromogenic substrate. Calculating the first 
derivative of the optical density vs time curve, after correcting for consumption of the 
chromogenic substrate, results in a thrombin generation curve. Consequently, the 
analysis of such a curve can, in principle, be carried out as described above. It is possible, 
however, to calculate the thrombin potential directly from the measured optical density 
vs time curve, bypassing the derivative calculation. 
During a measurement, a range of optical density (OD) readings are recorded 
together with corresponding time values. The concentration of the chromogenic sub- 
strate (S) can, at any moment be calculated from the optical density value: 
S(t) = S(0) - OD(C)l&, (20) 
E being the molar absorption coefficient of para-nitroaniline at a wavelength of 405 nm. 
At any moment, the conversion velocity of the substrate is the sum of the conversion 
velocities by thrombin and a,M-thrombin complex. As is evident from Table 1, the K,,, 
Table 1. Kinetic parameters of SQ 68 
Enzyme Conditions 
Thrombin Heated plasma 
Thrombin Buffer A 
a2M-Thrombin Serum 
K&M) + SE. k&e-‘)+S.E. 
819 f 19 0.38~0.002 
830 + 48 0.46+0&t 
788+ 11 0.29+0.01 
The kinetic parameters for thrombin conversion of the chromogenic 
substrate SO 68 were measured by measuring the rate of hydrolysis of SQ 68 
values in the range of 0-2OOO/cM by thrombin in a concentration of 100 nM, 
at 37°C. The k,,, and K, values were extracted from the substrate vs 
reaction rate curves using a non-linear fit procedure. 
286 H. KESSELS et al. 
, , 
I 
, 
, 
, 
, 
/ 
, 
/ 
, 
I 
I 
, 
, thrombin 
potential 
5 10 15 
time (min) 
Fig. 7. Time integral of the free thrombin concentration. The time course of the time integral of 
the thrombin concentration (-) as calculated from the time course of optical density measured 
during an integral thrombin generation experiment. The dashed line (---) shows the time course 
of the integral of the a,-macroglobulin-thrombin concentration. 
for SQ 68 by thrombin and a,M-thrombin are about equal, whereas their k,, values 
differ: 
dS 
= katl * T(t) * 
W) 
+ kcatz - wwt) * 
S(t) -- 
dt s(t) + Km S(t) + K,,,’ 
(21) 
which resolves into: 
AP(t) = TP(t) +fiMP(t) = 
S(0) -s(t) + K,,,(ln S(0) - In S(t)) 
k , (2W cat1 
with 
T(z) dt (22b) 
and 
Ml’(t) = 
I 
’ a,M(t) dr, Pc) 
0 
with f again equal to kcat21kcatl. This equation accounts for the consumption of chromo- 
genic substrate during the measurement. 
Integration of equation (4) gives the relationship between the time integral of the a,M 
concentration, M’(t), and the time integral of the thrombin concentration, TP(t): 
dMP(t) 
-=M(t)=k,. 
dt 
T(z) dt= kZ. TP(t) 
=k2.(AP(t)-f.MP(t)). (23) 
Thus the array of values for Ml’(t) can again be obtained by numerical integration of this 
equation, and the values of the thrombin integral can be calculated as: 
TP(ti) =AP(ti) -f* MP(ti). (24) 
Figure 7 shows an integral thrombin curve derived from a time curve of optical density. 
The thrombin potential now is the final level of the integral thrombin curve, as shown in 
the figure. 
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SUMMARY 
Measurement of thrombin generation in clotting plasma has undergone a revival 
during the last decade spurred by the synthesis of chromogenic oligopeptide substrates in 
the mid 1970s. Thrombin, being the central enzyme in haemostasis, is able to convey 
much useful information about the coagulation process [l]. Extracting this information 
from thrombin generation curves is often non-trivial, however. The first hurdle is the 
amidolytic activity of the complex of thrombin and a,-macroglobulin, which adds 
considerably to the signal measured both in normal and integral thrombin generation 
experiments [lo-121. This paper describes a mathematical procedure to strip the 
experimental data from their unwanted clothing. Much of the useful information from 
both normal and integral thrombin generation curves can be concentrated in one 
parameter, the thrombin potential, which is the time integral of the free thrombin 
concentration, and can easily be calculated from curves of the free thrombin concentra- 
tion [7]. It is sensitive to all known types of anticoagulant therapy. The time course of the 
rate of thrombin production, indicating the activity of the prothrombinase complex, can 
be calculated once the rate of inactivation of thrombin in plasma is known. Altered 
thrombin concentrations can in this way be shown to be due to increased inhibition of 
thrombin or to decreased formation of thrombin. It is shown how the time course of 
thrombin inactivation is inferred from the decay constants of thrombin for various 
thrombin inhibitors. For some of these inhibitors, namely AT111 and HCII, consumption 
of the inhibitor has to be taken into account. It is further shown how the rate of thrombin 
decay can be described in the presence of heparin. 
The development of an automatable method of measuring integral thrombin gener- 
ation curves has created the opportunity for the thrombin generation test to enter into 
the realm of clinical laboratory analysis [17]. Since, in this assay procedure, a chromo- 
genic substrate is present during thrombin generation and decay in plasma, the time 
integral of thrombin and azM-thrombin concentrations is recorded. The part of the 
signal due to a,M-thrombin can be subtracted in a procedure analogous to the 
calculation used for normal thrombin generation curves. The resulting curve contains all 
the information that is present in a normal thrombin generation curve. The inevitable 
consumption of the substrate during the clotting process is accounted for mathematically. 
The thrombin potential can be inferred from an integral thrombin generation curve 
without the need for calculating its derivative. 
All calculations presented in this article have been implemented in several computer 
programs (for IBM compatibles) which can be obtained from the authors. 
1. 
2. 
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